AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26223254 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (6 mm) alone
Number of subjects: 150
Study 26223254 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (8 mm) combined with osteotome sinus floor elevation (OSFE)
Number of subjects: 150
Study 26223254 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard implants (10 mm) combined with osteotome sinus floor elevation (OSFE)
Number of subjects: 150
Study 23532242 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (400 mg, twice daily)
Number of subjects: 117
Study 23532242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 20554506 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective retina therapy (SRT) using Q-switched Nd:YLF laser, wavelength 527 nm, t=1.7 μs, energy 100-370 μJ, spot diameter 200 μm, pulse repetition rate 100 Hz
Number of subjects: 30
Study 20554506 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective retina therapy (SRT)
Number of subjects: 30
Study 20554506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment initially)
Number of subjects: 30
Study 20554506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over group treated with SRT after initial control
Number of subjects: 30
Study 18929279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg/kg (Group A)
Number of subjects: 75
Study 18929279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg/kg (Group B)
Number of subjects: 75
Study 18929279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.2 mg/kg (Group C)
Number of subjects: 75
Study 16369133 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided group
Number of subjects: 50
Study 16369133 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 14652364 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg elemental iron with 1 mg riboflavin
Number of subjects: 799
Study 14652364 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg elemental zinc with 1 mg riboflavin
Number of subjects: 799
Study 14652364 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg iron and 20 mg zinc with 1 mg riboflavin
Number of subjects: 799
Study 14652364 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient mix (MM) containing 20 mg iron, 20 mg zinc, 1 mg riboflavin along with other minerals and vitamins
Number of subjects: 799
Study 14652364 — intervention group
Group type: COMPARATOR
Intervention: Control treatment, 1 mg riboflavin only
Number of subjects: 799
Study 14652364 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron + zinc supplementation
Number of subjects: 799
Study 11020543 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines prescribed (70%)
Number of subjects: 50
Study 11020543 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive disorders
Number of subjects: 50
Study 11020543 — intervention group
Group type: EXPERIMENTAL
Intervention: Irritability as a symptom
Number of subjects: 50
Study 8618584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive primary care intervention (close follow-up by a nurse and primary care physician for six months)
Number of subjects: 1396
Study 8618584 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1396
Study 1452950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement containing protein (20.4 g), mineral salts (Ca: 0.525 g), and vitamins A = 750 IU; D3 = 25 IU, 250 ml/day for a mean of 38 days
Number of subjects: 62
Study 1452950 — intervention group
Group type: COMPARATOR
Intervention: Control group received the same supplement dose but with no protein, 250 ml/day for a mean of 38 days
Number of subjects: 62
Study 1452950 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-supplemented group
Number of subjects: 62
Study 1452950 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 6362490 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of epinephrine
Number of subjects: 50
Study 6362490 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of epinephrine
Number of subjects: 50
Study 6362490 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of phenylephrine
Number of subjects: 50
Study 6362490 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of phenylephrine
Number of subjects: 50
Study 6362490 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine and phenylephrine (at equipotent doses)
Number of subjects: 50
Study 30275690 — intervention group
Group type: EXPERIMENTAL
Intervention: GLY 25 µg twice daily
Number of subjects: 2379
Study 30275690 — intervention group
Group type: EXPERIMENTAL
Intervention: GLY 50 µg twice daily
Number of subjects: 2379
Study 30275690 — intervention group
Group type: COMPARATOR
Intervention: TIO 18 µg once daily
Number of subjects: 2379
Study 27417981 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 0
Study 27417981 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 0
Study 24266596 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of 1000 units of human pasteurized C1‐INH concentrate
Number of subjects: 24
Study 24266596 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of 1000 units of human pasteurized C1‐INH concentrate
Number of subjects: 24
Study 22866996 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Nidra relaxation preceded by Hatha yoga (YR)
Number of subjects: 20
Study 22866996 — intervention group
Group type: COMPARATOR
Intervention: Yoga Nidra relaxation only (R)
Number of subjects: 20
Study 20117960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-osmotic saline drops (280mmol/kg)
Number of subjects: 15
Study 20117960 — intervention group
Group type: COMPARATOR
Intervention: Hyper-osmotic saline drops (380mmol/kg)
Number of subjects: 15
Study 20117960 — intervention group
Group type: COMPARATOR
Intervention: Hypo-osmotic saline drops (280mmol/kg) and Hyper-osmotic saline drops (380mmol/kg)
Number of subjects: 15
Study 18310627 — intervention group
Group type: EXPERIMENTAL
Intervention: Synera patch and saline infiltration
Number of subjects: 0
Study 18310627 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch and 2% lidocaine infiltration
Number of subjects: 0
Study 15808659 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (1.5 mg/kg per dose during the anhepatic period and two doses every other day)
Number of subjects: 22
Study 15808659 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 22
Study 15808659 — intervention group
Group type: COMPARATOR
Intervention: No thymoglobulin (control group)
Number of subjects: 22
Study 14652238 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 803
Study 14652238 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-(OH) vitamin D levels
Number of subjects: 803
Study 14652238 — intervention group
Group type: COMPARATOR
Intervention: VDR polymorphisms
Number of subjects: 803
Study 10653826 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 3522
Study 10653826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3522
Study 9015776 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen specific immunotherapy (IT)
Number of subjects: 31
Study 9015776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9015776 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen specific immunotherapy (IT) with grass pollen extracts
Number of subjects: 31
Study 1615900 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) of 1757 kJ/d for 1-2 months
Number of subjects: 45
Study 1615900 — intervention group
Group type: COMPARATOR
Intervention: Supplemental low-calorie diet (LCD) of 3515-5021 kJ/d for 1-2 months
Number of subjects: 45
Study 1615900 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD)
Number of subjects: 45
Study 1615900 — intervention group
Group type: COMPARATOR
Intervention: Supplemental low-calorie diet (LCD)
Number of subjects: 45
Study 6423045 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical lunchtime demonstrations (group 2)
Number of subjects: 40
Study 6423045 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape education (group 3)
Number of subjects: 40
Study 6423045 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet sheet instruction (group 1)
Number of subjects: 40
Study 29991952 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuzijue exercise combined with elastic band resistance exercise (LEG)
Number of subjects: 60
Study 29991952 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuzijue exercise (LG)
Number of subjects: 60
Study 29991952 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study 25491541 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acupoints BL23 and KI3
Number of subjects: 58
Study 25491541 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint BL23
Number of subjects: 58
Study 25491541 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint SP6
Number of subjects: 58
Study 25211605 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Skin Allograft (HSA)
Number of subjects: 23
Study 25211605 — intervention group
Group type: COMPARATOR
Intervention: Human Fibroblast-Derived Dermal Skin (HFDS)
Number of subjects: 23
Study 22619396 — intervention group
Group type: COMPARATOR
Intervention: Single context condition
Number of subjects: 52
Study 22619396 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple context condition
Number of subjects: 52
Study 20016147 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of stabilized rice bran once daily for 12 weeks
Number of subjects: 28
Study 20016147 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 28
Study 17483102 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-oriented group homes
Number of subjects: 112
Study 17483102 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent apartments
Number of subjects: 112
Study 17483102 — intervention group
Group type: EXPERIMENTAL
Intervention: Group home
Number of subjects: 112
Study 16305864 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer closure with suction drain
Number of subjects: 78
Study 16305864 — intervention group
Group type: COMPARATOR
Intervention: Multiple-layer closure
Number of subjects: 78
Study 11915458 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamization of interlocking nails
Number of subjects: 50
Study 11915458 — intervention group
Group type: COMPARATOR
Intervention: No dynamization
Number of subjects: 50
Study 11075561 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP (0.1 microgram.kg‐1.min‐1)
Number of subjects: 13
Study 11075561 — intervention group
Group type: COMPARATOR
Intervention: Control (no hANP infusion)
Number of subjects: 13
Study 9147122 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (AmF/SnF2) dentifrice
Number of subjects: 246
Study 9147122 — intervention group
Group type: COMPARATOR
Intervention: NaF dentifrice
Number of subjects: 246
Study 1315827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium, low-fat/high-fibre diet (less than 60 mmol sodium/day; 30% fat energy; P:S ratio = 1; 30-50 g fibre/day)
Number of subjects: 95
Study 1315827 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium, normal-fat/normal-fibre diet (less than 60 mmol sodium/day; 40% fat energy; P:S ratio = 0.3; 15 g fibre/day)
Number of subjects: 95
Study 1315827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium, low-fat/high-fibre diet
Number of subjects: 95
Study 1315827 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium, normal-fat/normal-fibre diet
Number of subjects: 95
Study 3889076 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg/d for days 1-6, 360 mg/d for days 7-12)
Number of subjects: 30
Study 3889076 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/d for days 1-6, 480 mg/d for days 7-12)
Number of subjects: 30
Study 3889076 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (combined with quinidine 750 mg/d for part III)
Number of subjects: 30
Study 3889076 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (750 mg/d for part III)
Number of subjects: 30
Study 31041591 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available meal replacement product (2 servings/day) + other supplements
Number of subjects: 0
Study 31041591 — intervention group
Group type: COMPARATOR
Intervention: New meal replacement (2 servings/day)
Number of subjects: 0
Study 29662303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterimar Mn nasal spray (4 puffs/day) for 5 months
Number of subjects: 60
Study 29662303 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study 26372606 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g sucrose in 500 mL water
Number of subjects: 90
Study 26372606 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g sucrose in 500 mL water
Number of subjects: 90
Study 26372606 — intervention group
Group type: COMPARATOR
Intervention: 0 g sucrose (control)
Number of subjects: 90
Study 24758775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and electrical stimulation through the needle
Number of subjects: 437
Study 24758775 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound alone
Number of subjects: 437
Study 22307942 — intervention group
Group type: EXPERIMENTAL
Intervention: OCR 200 mg + MTX
Number of subjects: 613
Study 22307942 — intervention group
Group type: EXPERIMENTAL
Intervention: OCR 500 mg + MTX
Number of subjects: 613
Study 22307942 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 613
Study 20102728 — intervention group
Group type: COMPARATOR
Intervention: Smelling chocolate (n=6)
Number of subjects: 12
Study 20102728 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating chocolate (n=6)
Number of subjects: 12
Study 17438216 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 8 mg/24 hours
Number of subjects: 351
Study 17438216 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 12 mg/24 hours
Number of subjects: 351
Study 17438216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 16123321 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 32
Study 12183307 — intervention group
Group type: EXPERIMENTAL
Intervention: Handrubbing with alcohol based solution (n=12)
Number of subjects: 23
Study 12183307 — intervention group
Group type: COMPARATOR
Intervention: Handwashing with antiseptic soap (n=11)
Number of subjects: 23
Study 10093648 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (propofol/remifentanil)
Number of subjects: 105
Study 10093648 — intervention group
Group type: COMPARATOR
Intervention: VOLATIL (sevoflurane/N2O)
Number of subjects: 105
Study 10093648 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fixation suture (faden-operation)
Number of subjects: 105
Study 10093648 — intervention group
Group type: EXPERIMENTAL
Intervention: Other operations
Number of subjects: 105
Study 10093648 — intervention group
Group type: EXPERIMENTAL
Intervention: Recessions
Number of subjects: 105
Study 7762503 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 462
Study 7762503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 1969402 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg twice daily (A)
Number of subjects: 24
Study 1969402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 40 mg twice daily (N)
Number of subjects: 24
Study 1969402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 24
Study 31437456 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-325
Number of subjects: 20
Study 31437456 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 20
Study 31169651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral subcostal TAP block with 20 ml of levobupivacaine 0.375% and epinephrine 5 μg/ml
Number of subjects: 60
Study 31169651 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline with epinephrine 5 μg/ml (Control)
Number of subjects: 60
Study 27233381 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urine potassium excretion (measured as 1-SD increase in baseline urine potassium level)
Number of subjects: 812
Study 26410153 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine plus buccal and lingual infiltration and preoperative oral ketorolac
Number of subjects: 150
Study 26410153 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine plus buccal and lingual infiltration
Number of subjects: 150
Study 26410153 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine plus buccal and lingual infiltration
Number of subjects: 150
Study 23482074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) turned on
Number of subjects: 63
Study 23482074 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) turned off
Number of subjects: 63
Study 21677021 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) targeting lower limb muscles, twice a week for 10 weeks
Number of subjects: 71
Study 21677021 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus attention and social program, once a week for 10 weeks
Number of subjects: 71
Study 18774342 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mind-body self-care intervention (n = 41)
Number of subjects: 78
Study 18774342 — intervention group
Group type: COMPARATOR
Intervention: Waiting list comparison group (n = 37)
Number of subjects: 78
Study 17091411 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention program consisting of education, ergonomics, exercises, pain management, advice for daily life movement, pelvic belt/crutches, and information about delivery (n=275)
Number of subjects: 569
Study 17091411 — intervention group
Group type: COMPARATOR
Intervention: Control group with no treatment (n=285)
Number of subjects: 569
Study 14742987 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate (AmBd)
Number of subjects: 100
Study 14742987 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC)
Number of subjects: 100
Study 11311619 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA IOL
Number of subjects: 137
Study 11311619 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 137
Study 11311619 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft acrylic IOL
Number of subjects: 137
Study 11311619 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 137
Study 9461266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (single shot)
Number of subjects: 1009
Study 9461266 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin-netilmicin (4-day regimen)
Number of subjects: 1009
Study 7929709 — intervention group
Group type: COMPARATOR
Intervention: California Verbal Learning Test (CVLT) - Tulving and Colotla measure
Number of subjects: 13
Study 7929709 — intervention group
Group type: COMPARATOR
Intervention: California Verbal Learning Test (CVLT) - recall from recency measure
Number of subjects: 13
Study 7929709 — intervention group
Group type: COMPARATOR
Intervention: California Verbal Learning Test (CVLT) - secondary memory (SM) measures
Number of subjects: 13
Study 7929709 — intervention group
Group type: COMPARATOR
Intervention: California Verbal Learning Test (CVLT) - clustering words by taxonomic category
Number of subjects: 13
Study 3283622 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan
Number of subjects: 321
Study 3283622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 321
Study 3283622 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 321
Study 29991131 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (singing group)
Number of subjects: 298
Study 29991131 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyric reading group
Number of subjects: 298
Study 29991131 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 298
Study 28456851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (n = 107)
Number of subjects: 107
Study 28456851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib crossover (n = 97)
Number of subjects: 107
Study 28456851 — intervention group
Group type: COMPARATOR
Intervention: Interferon as BAT (n = 13)
Number of subjects: 107
Study 25758457 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable intraoral vibrational device (AcceleDent; n = 29)
Number of subjects: 81
Study 25758457 — intervention group
Group type: COMPARATOR
Intervention: Identical nonfunctional (sham) device (n = 25)
Number of subjects: 81
Study 25758457 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliances only (n = 27)
Number of subjects: 81
Study 23845666 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMS‐Ajust
Number of subjects: 137
Study 23845666 — intervention group
Group type: COMPARATOR
Intervention: TVT‐O
Number of subjects: 137
Study 20805754 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/dexmedetomidine
Number of subjects: 50
Study 20805754 — intervention group
Group type: COMPARATOR
Intervention: Propofol/fentanyl
Number of subjects: 50
Study 19043908 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated group program involving social group work intervention and Chinese medicine therapeutics
Number of subjects: 28
Study 19043908 — intervention group
Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 28
Study 16390558 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% albumin (colloid priming)
Number of subjects: 22
Study 16390558 — intervention group
Group type: COMPARATOR
Intervention: Pure crystalloid priming solution
Number of subjects: 22
Study 12804730 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 409
Study 12804730 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1C AAM
Number of subjects: 409
Study 12804730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 409